Braak stage 1, 100% of pigmented neurons left
parkinsonconnecting

Gene record

GLRA3

glycine receptor alpha 3

translation score 0.61, read 2026-10-26; 1 sealed predictions, 0 held; 1 receipts.

Six readers

readerfoundscore
genetics
Open Targets
no genetic evidence; overall 0.01 from other evidence0.00
cell type
Human Protein Atlas
cell type enhanced, including other brain neurons; strongest in retinal amacrine cells0.75
chemistry
Open Targets
a small-molecule pocket0.60
trials
ClinicalTrials.gov
no Parkinson's trials on record: an open field1.00
literature
PubMed
no papers tie it to Parkinson's yet1.00
pathways
Reactome
1 pathway; mostly dopamine synapse1.00
proposal for GLRA3, translation score 0.61

Knock down and overexpress GLRA3 in dopamine neurons; measure evoked dopamine release and dopamine transporter uptake and survival of TH-positive neurons and phospho-α-synuclein (pS129) inclusions after seeding with α-synuclein fibrils.

Cell type
dopamine neurons
Direction
Both arms: public data does not say which way helps.
Molecular readout
evoked dopamine release and dopamine transporter uptake
Functional readout
survival of TH-positive neurons and phospho-α-synuclein (pS129) inclusions after seeding with α-synuclein fibrils
Rule-out
If neither arm moves evoked dopamine release by 20% or more against non-targeting and empty-vector controls, across three independent differentiations, the hypothesis is wrong.
Lab request
CRISPRi knockdown and lentiviral overexpression of GLRA3 in iPSC-derived midbrain dopamine neurons (FOXA2+, LMX1A+, TH+); n = 3 differentiations; readouts: evoked dopamine release and dopamine transporter uptake; survival of TH-positive neurons and phospho-α-synuclein (pS129) inclusions after seeding with α-synuclein fibrils. Controls: non-targeting guide, empty vector. About 8 to 10 weeks, most of it differentiation.

Sealed predictions

  1. GLRA3 in dopamine neurons, braak+0.49 (p 0.177) → +0.64 (p 0.063)receipt 10773

Swarm cases

receipt 10773: GLRA3 in dopamine neurons, braak

power
full sample +0.47 (p 0.049, n 18), 95% CI +0.01 to +0.77. the interval excludes zero: something may be there, smaller than a half can see.
confounder
adjusted for sex: +0.53 (p 0.024, n 18). holds up.
composition
dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.51 (p 0.029, n 18). not the mix.
skeptic
leave-one-out range +0.40 to +0.59, sign flips 0; without severely affected donors +0.47 (p 0.049, n 18). robust.
cell type
no other cell group does better.
axis
no measure beats "tracks Braak Lewy-body stage" for GLRA3 in dopamine neurons.

case closed: nothing better to follow up.

Receipts

loading the receipts